Eledon Pharmaceuticals Logo
US28617K1016
A2QL00
ELDN

Eledon Pharmaceuticals

Prognose

Analytikernes gennemsnitlige kursmål er 4,56 € (+178,05 %). Medianen er 4,56 € (+178,05 %).

Køb
  4
Behold
  0
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Eledon applies to FDA for Tegoprubart indication in islet cell transplantation

    Eledon has filed an investigational new drug (IND) application with the FDA for a registration‑enabling study of the anti‑CD40L antibody Tegoprubart for immunosuppression in islet cell transplants for type 1 diabetes. The study would be Eledon’s first company‑sponsored trial in this area; investigator‑initiated studies are already underway at UChicago, Duke and MGH, and compassionate‑use treatments are also being provided. Earlier results in 12 treated patients showed insulin independence, HbA1c <7.0% and stable graft function for up to 22 months; Eledon also plans to start the global phase‑3 LEGACY study in kidney transplantation in Q4 2026 with about 600 patients. » Mere på de.investing.com


  • Eledon Pharmaceuticals presents phase‑2 results and plans phase‑3 alignment with FDA

    At the Leerink conference, Eledon Pharmaceuticals presented data on tegoprubart in kidney transplants, showing non‑inferiority to tacrolimus and a better safety profile, but no statistically significant superiority in kidney function. The company plans to finalize the phase‑3 study design with the FDA by year‑end and aims to start the trial within the year. Eledon received orphan‑drug designation for liver transplantation, is planning a liver‑related investigator‑sponsored trial (IST), and is evaluating expansion and strategic partnerships in islet‑cell transplantation. Cash on hand exceeds $130 million, providing a runway into the second quarter of next year. » Mere på de.investing.com


  • Eledon Pharmaceuticals plans phase‑3 for Tegoprubart despite missed endpoints

    At the Guggenheim Summit Eledon Pharmaceuticals said Tegoprubart showed significant safety advantages in kidney transplant studies, but the phase‑2 BESTOW trial missed its primary endpoint for renal function. The company plans to start a registrational phase‑3 trial with a composite endpoint by the end of 2026 and intends to place greater emphasis on patient‑reported outcomes. Positive early results in islet‑cell transplantation are to be advanced into a sponsored study in 2026, with an IND filing planned by year‑end. Eledon has funding into the second quarter of 2027 and is also pursuing global collaborations in xenotransplantation. » Mere på de.investing.com


  • Eledon: 24-month data on tegoprubart show improved kidney function and no rejections

    Eledon presented 24-month follow-up data from eight patients in the phase‑1b study of tegoprubart in kidney transplantation. Mean eGFR increased from 67.0 ml/min/1.73 m² at 12 months to 74.2 ml/min/1.73 m² at 24 months; there were no biopsy‑confirmed acute rejection episodes, graft losses, deaths, new-onset diabetes, or donor-specific antibodies reported. Tegoprubart is an anti‑CD40L antibody being investigated as a non‑lymphocyte‑depleting immunomodulatory therapy. Financials show a solid balance sheet with a high current ratio and more cash than debt, providing runway for the clinical programs. » Mere på de.investing.com


  • Eledon Pharmaceuticals stock rises after positive Tegoprubart data on islet cell transplantation

    Eledon Pharmaceuticals’ stock climbed about 3.3% in after-hours trading following preliminary study results for Tegoprubart in type 1 diabetes. In the ongoing University of Chicago Medicine trial, all six initial patients achieved insulin independence after one or two islet cell transplants, some for more than a year, accompanied by low HbA1c levels. Tegoprubart was well tolerated with no serious infections, thromboembolic events, rejection, or signs of kidney or neurological toxicity. The study has been expanded to 12 participants and is funded by Breakthrough T1D, which also plans to support a second study in patients with chronic kidney disease. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Eledon Pharmaceuticals en omsætning på 0 € og et nettoresultat på -3,47 mio. €

(EUR) september 2026
YoY
Omsætning 0 -
Bruttofortjeneste 0 -
Nettoresultat -3,47 mio. 76,66 %
EBITDA -3,47 mio. 76,66 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
146,25 mio. €
Antal aktier
84,46 mio.
Højeste/laveste i 52 uger
4,09 € - 1,23 €
Udbytte Nej
Beta
0,85
P/E (PE Ratio)
-2,41
PEG (PEG Ratio)
0,17
K/I (PB Ratio)
3,12
P/S (PS Ratio)
0,00

Virksomhedsprofil

Eledon Pharmaceuticals, Inc., et biofarmaceutisk selskab i klinisk fase, fokuserer på udvikling af lægemidler til patienter med autoimmune sygdomme og amyotrofisk lateral sklerose (ALS), og som har behov for en organ- eller celletransplantation. Selskabets førende produktkandidat er AT-1501, en humaniseret monoklonal antistof rettet mod CD40-ligand, et molekyle, der udtrykkes på overfladen af menneskets immunsystems T-celler, og som er i fase 2a-kliniske forsøg til behandling af ALS samt i fase 2-kliniske forsøg med øcelletransplantation til behandling af type 1-diabetes. Selskabet var tidligere kendt som Novus Therapeutics, Inc. og ændrede navn til Eledon Pharmaceuticals, Inc. i januar 2021. Eledon Pharmaceuticals, Inc. har hovedkontor i Irvine, Californien.

Navn
Eledon Pharmaceuticals
CEO
David-Alexandre C. Gros
Hjemsted Irvine, ca
USA
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
17.09.2014
Medarbejdere 33

Tickersymboler

Børs Symbol
NASDAQ
ELDN
Frankfurt
2TK.F
München
2TK.MU
Düsseldorf
2TK.DU
🍪

Parqet  bruger cookies. Læs mere